+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Melanoma Drug"

Melanoma Therapeutics: Global Markets - Product Thumbnail Image

Melanoma Therapeutics: Global Markets

  • Report
  • November 2023
  • 131 Pages
  • Global
From
Melanoma Therapeutics Global Market Report 2024 - Product Thumbnail Image

Melanoma Therapeutics Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Melanoma Drugs Global Market Report 2024 - Product Thumbnail Image

Melanoma Drugs Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Melanoma Therapeutics: Global Strategic Business Report - Product Thumbnail Image

Melanoma Therapeutics: Global Strategic Business Report

  • Report
  • April 2024
  • 162 Pages
  • Global
From
Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
From
Malignant Melanoma Treatment Global Market Report 2024 - Product Thumbnail Image

Malignant Melanoma Treatment Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Malignant Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Malignant Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Unresectable Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Unresectable Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Metastatic Cutaneous Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Cutaneous Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Untreated Metastatic or Unresectable Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Untreated Metastatic or Unresectable Melanoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
BRAF-Mutant Metastatic Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

BRAF-Mutant Metastatic Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Metastatic Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
Uveal Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Uveal Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 90 Pages
  • Global
From
Metastatic Uveal Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Uveal Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Refractory Metastatic Melanoma - Pipeline Insight, 2024 - Product Thumbnail Image

Refractory Metastatic Melanoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
From
Loading Indicator

The Melanoma Drug market is a subset of the larger Skin Cancer Drugs market. It is composed of drugs used to treat melanoma, a type of skin cancer. These drugs are typically used in combination with other treatments such as surgery, radiation, and immunotherapy. Commonly used drugs include targeted therapies, immunotherapies, and chemotherapy. Targeted therapies are designed to target specific molecules in the cancer cells, while immunotherapies are designed to boost the body's own immune system to fight the cancer. Chemotherapy is used to kill cancer cells. The Melanoma Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck, Roche, Novartis, and Pfizer. Other companies include AstraZeneca, Eli Lilly, and GlaxoSmithKline. Show Less Read more